Eli Lilly Reports Strong Q1 2026 Earnings, Raised Guidance Due to Mounjaro and Zepbound Sales
Eli Lilly reported a 56% increase in Q1 2026 revenue to $19.8 billion, driven by strong sales of its obesity and diabetes drugs Zepbound and Mounjaro. The company raised its full-year 2026 revenue guidance to $82 billion to $85 billion from $80 billion to $83 billion. Adjusted earnings per share also increased significantly, exceeding analyst expectations.
Tickers: $LLY
Topics: Drug Sales Earnings Guidance Update Pharmaceutical Industry Revenue Growth